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Objectives:  Persistent  hepatitis  B  virus  (HBV)  infection  is  a  major  cause  of  morbidity  and  mortality  in
sub-Saharan  Africa.  The  HIV epidemic  has  the  potential  to  affect  its  biology.  Immunisation  protocols
established  in  the  pre-HIV  era  are  based  upon  data  showing  predominantly  horizontal  infant  transmis-
sion.  This  study  aimed  to determine  whether  HIV  co-infection  will  change  the  epidemiology  of  HBV  both
by  increasing  infectivity  and  by favouring  the  escape  of viruses  bearing  phenotypically  altered  HBsAg.
Methods:  This  retrospective  cross-sectional  study  used  antenatal  samples  from  the  2008  Antenatal  Sen-
tinel HIV and  Syphilis  Prevalence  Survey  in the  Western  Cape,  South  Africa.  All HIV-infected  women
were  age  and race-matched  to HIV-uninfected  women.  Samples  were  tested  for serological  markers  of
HBV  and  HDV infection.  HBV  viral load,  consensus  sequencing  and  genotyping  were  performed.  Luminex
technology  was  used  to determine  HBsAg  phenotype.  All  samples  from  HIV-infected  women  were  tested
for traces  of  antiretroviral  drugs  by mass  spectrometry.
Results:  This study  showed  a trend  toward  loss  of immune  control  of  HBV  in  HIV-infected  women  with  3.4%
of  samples  containing  HBsAg,  18.9%  contained  HBeAg.  In  contrast,  2.9%  of  samples  from  HIV-uninfected
women  contained  HBsAg  and  17.1%  of  these  HBeAg.  The  median  HBV  load  in  the  HIV-infected  group  was
9.72  ×  107 IU/ml  and  in the  HIV-uninfected  group  1.19  × 106 IU/ml.  Genotyping  showed  63/68 samples
belonged  to genotype  A  and  the remainder  genotype  D. Mutations  in  the  precore  region  were  found  in
35%  and 33%  of  samples  from  HIV-infected  and  HIV-uninfected  respectively.  Although  no  major  epitope
ablation  was  found,  marked  variation  in  HBsAg  proﬁles  in  HIV-infected  group  was  demonstrated.  No HDV
infection  was detected.
Conclusion: HIV-HBV  co-infected  women  exhibit  a  degree  of  immune  escape.  One  in six HBV-infected
pregnant  women,  irrespective  of  HIV status  is  HBeAg  seropositive.  HBV  immunization  of  newborns  in
sub-Saharan  Africa  should  be implemented.. IntroductionChronic hepatitis B virus (HBV) infection is a major cause of
orbidity and mortality in sub-Saharan Africa (SSA) [1] despite
 This is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
∗ Corresponding author at: Division of Medical Virology, Department of Pathol-
gy, Stellenbosch University, Faculty of Medicine and Health Sciences, Francie van
ijl Avenue, Tygerberg Campus, Western Cape Province, South Africa 7505.
E-mail address: andersson m@sun.ac.za (M.I. Andersson).
264-410X/$ – see front matter ©  2013 The Authors. Published by Elsevier Ltd. All rights 
ttp://dx.doi.org/10.1016/j.vaccine.2013.08.028© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
the availability for the last three decades of a safe and effective
vaccine. Various parameters of HBV infection are altered by the
immunosuppression caused by human immunodeﬁciency virus
(HIV) infection. Those persons co-infected have a greater preva-
lence of HBV e antigen (HBeAg) which is a marker for infectivity [2],
higher HBV DNA levels [3], more frequent HBV reactivation [4] and a
higher prevalence of occult HBV infection [5]. Two resulting aspects
of particular concern are higher infectivity facilitating HBV onward
transmission and the potential for generation of immune escape
variants during reactivation. The nature of HBV infection in preg-
nant women  is important as it determines the risk of transmission
of HBV to their infants in utero [6] and during parturition [7]. Despite
reserved.
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his important relationship there are few data describing the viral
arameters of HBV infection in HIV co-infected pregnant women.
HBV immunisation protocols for the prevention of infection in
arly life in many African countries are based on data from the
re-HIV era which indicated that HBV infection occurred predom-
nantly horizontally between siblings and play-mates rather than
ertically from mother to child [8,9]. These protocols are there-
ore aimed at preventing horizontal transmission during childhood
ather than preventing maternal–infant transmission at birth. As a
onsequence the ﬁrst dose of vaccine is given later in the postnatal
eriod rather than as close to parturition as possible, leaving the
eonate susceptible to infection from exposure at birth. Further-
ore there is no antenatal screening programme for HBV in South
frica, nor in much of SSA.
The escape of HBV from a partially incapacitated host immune
ystem is often associated with the generation of viral variants
earing changes in the HBV surface antigen (HBsAg). Transmission
f these variants to infants has the potential to establish them in the
eneral population. Phenotypic changes in HBsAg may  reduce the
fﬁcacy of the current recombinant hepatitis B vaccines based on
he short HBsAg transcript and promote the propagation of immune
scape variants.
This study aimed to determine whether there is evidence to
upport the hypothesis that HIV co-infection will change the epi-
emiology of HBV both by increasing infectivity and by favouring
he escape of viruses bearing phenotypically altered HBsAg.
. Materials and methods
This retrospective, cross-sectional study used antenatal samples
ollected for the 2008 Antenatal Sentinel HIV and Syphilis Preva-
ence Survey [10] in the Western Cape Province of South Africa. All
IV-infected women from whom samples were available were ran-
omly age- and race-matched to HIV-uninfected women. Approval
as obtained from the University of Stellenbosch Health Research
thics Committee and from the Provincial and National Depart-
ents of Health.
.1. Recruitment of patients
Of the 9355 pregnant women recruited from antenatal clin-
cs around the Western Cape for the 2008 survey, 1549 were
eropositive for anti-HIV and were matched for age and race to
550 HIV-uninfected women. Of the 3099 serum samples from
hese individuals, ten were haemolysed and discarded as unsuit-
ble for testing. The remaining 3089 samples comprising 1546
IV-uninfected and 1543 HIV-infected survey participants were
ncluded in the study. The date of HIV infection, the degree of
mmunosuppression and CD4 count were not available for the HIV-
nfected women.
.2. HBV serological and molecular testing
Samples were tested for HBsAg using the Abbott AxSYM
Abbott Diagnostics, Chicago, IL). All samples initially reactive for
BsAg were conﬁrmed by neutralisation using high titre human
ntibody to HBsAg (anti-HBs) in the Abbott Murex HBsAg GE34/36
mmunoassay kit (Murex Biotech, Kent, England). Samples con-
rmed to contain HBsAg were tested for HBeAg and antibodies to
BeAg (anti-HBe) using DiaSorin ETI-EBK PLUS and ETI-AB-EBK
LUS immunoassay kits (DiaSorin, Saluggia, Italy). Testing for
ntibody to the hepatitis Delta Virus (anti-HDV) was performed
n all available HBsAg-positive samples using ETI-AB-DELTAK-2
DiaSorin).
HBV DNA quantiﬁcation, consensus sequencing and genotyp-
ng were performed as previously described [11–13], on samples 31 (2013) 5579– 5584
containing HBsAg. Sequence analysis was performed using DNAS-
TAR (version 9).
Alignments of 1800 sequences representing all described geno-
types/subgenotypes were obtained from either in-house generated
sequences or from GenBank. The sequences were checked both
visually and by Position Speciﬁc Scoring Matrix to identify intra-
genotypic motifs. Amino acid alignments for wild-type consensus
genotype speciﬁc sequences were created for the basal core pro-
moter, precore, polymerase and HBsAg regions and used to identify
mutations. Genotype determination was  based on clustering within
phylogenetic trees generated using the 1800 representative HBsAg
nucleotide sequences.
2.3. HBsAg phenotyping
The impact of the observed amino acid changes on HBsAg
antigenicity was investigated via ex vivo HBsAg phenotyping as
previously described [14]. Brieﬂy, Luminex technology was used to
measure the interaction of plasma HBsAg with three monoclonal
antibodies (mAbs) directed against different epitopes of the “a”
determinant of HBsAg. The alteration of HBsAg antigenicity was
deﬁned by changes in the pattern of reactivity on the individual
solid-phase monoclonal antibodies exceeding 2 SD of the mean
when compared to expected wild type reactivity. Only samples
from women infected with HBV genotype A whose plasma HBsAg
was reactive in the phenotyping assays at a level equivalent to or
greater than 50 IU/ml were included.
2.4. Antiretroviral drug residue testing
At the time of this study ﬁrst line therapy for HIV infected
pregnant women  with a CD4 count less than 200 cells/mm3 was
zidovudine plus lamivudine plus efavirenz or nevirapine. For those
women with a CD4 count greater than 200 cells/mm3, zidovudine
alone was administered. For those who failed ﬁrst line therapy,
a combination using lopinavir was  prescribed. Tenofovir therapy
was available for those patients who were known to be HBsAg
positive. Lamivudine was  used as a surrogate for tenofovir as all
women on tenofovir were also administered lamivudine. In order to
identify those women on combination antiretroviral therapy, and
in particular those on HBV-active therapy, all samples from HIV-
infected women were tested for traces of lamivudine, lopinavir,
efavirenz and nevirapine by mass spectrometry, as described
previously [15].
2.5. Statistical analysis
Categorical variables were described using number and percent-
ages. Quantitative variables were expressed as a mean and standard
deviation if normally distributed or median and interquartile range
if not normally distributed. Pearson’s chi squared test was used
to determine association between independent variables, however
where numbers in a cell were less than ﬁve, a Fisher’s exact test
was used instead. Student’s t-test was  used to examine the asso-
ciation between HIV status and HBV viral load and age and HBeAg
status. ANOVA was  used to determine if there was  any associa-
tion between HBsAg status and age, education level, or parity. All
reported p values are for two-tailed tests. Data was analysed using
Statistica, version 11 (StatSoft Inc., OK, USA).
3. Results3.1. Demographics
The basic demographic data of the study cohort are shown in
Table 1.
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Table 1
Basic demographic data for the age- and sex-matched cohorts of HIV-infected
(n  = 1543) and HIV-uninfected (n = 1546) antenatal clinic attendees from the West-
ern Cape.
HIV-uninfected (n = 1546) HIV-infected (n = 1543)
Age Median 26 yrs Median 26.8 yrs
(IQR 23,31) (IQR 23,31)
(Range 12–44) (Range 12–44)
Black 1297 (83.9%) 1323 (85.7%)
Coloured 203 (13.1%) 179 (11.6%)
Other/unknown 46 (3.0%) 41 (2.7%)
Education ≤ gd10a 998 (64.6%) 886 (57.4%)
Parity Median 1 Median 1
(IQR 0,2) (IQR 0,2)
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a Secondary school.
.2. HBV and HDV serology
Ninety-seven samples from the 3089 studied were conﬁrmed
o contain HBsAg; the prevalence in HIV-uninfected pregnant
omen was 2.9% (44/1546) compared with 3.4% (53/1543) in HIV-
nfected pregnant women (Table 2). A signiﬁcant association was
ound between HBsAg seropositivity and a lower educational grade
p = 0.03), but not between HBsAg status and HIV status (p = 0.404),
ge (p = 0.52) or parity (p = 0.27). All HBsAg-positive samples of suf-
cient volume (87) were tested for anti-HDV and all were negative.
.3. HBeAg prevalence
Only 94 samples were of sufﬁcient volume for HBeAg testing of
hich 17 contained HBeAg but no anti-HBe, 7/41 (17.1%) in the HIV-
ninfected group compared with 10/53 (18.9%) in the HIV-infected
roup (Table 2). In the HIV-uninfected group, one sample contained
either HBeAg nor anti-HBe and one contained both antibody
nd antigen. In the HIV-uninfected group, the HBeAg seropositive
others were signiﬁcantly younger than the HBeAg seronegative
others (21.7 yrs SD = 5.59 vs. 27.6 yrs SD = 4.74, p = 0.016). In con-
rast, there was no signiﬁcant difference in age between HBeAg
eropositive and seronegative women in the HIV-infected group.
.4. HBV DNA levels
In those samples from mothers who were seropositive
or HBeAg, the HBV DNA was of similar range, but the
edian was different, in those seven not infected with HIV
120–260,000,000 IU/ml, median 1.19 × 106 IU/ml) and those ten
IV-infected (190–560,000,000 IU/ml, median 9.72 × 107 IU/ml)
Fig. 1 and Table 2).
The serum HBV DNA was below the level of detection in 14/75
hose serum contained anti-HBe. The proportion in whom DNA
able 2
BV serology and HBV DNA levels in samples from HIV-uninfected and HIV-infected
ntenatal clinic attendees.
HIV-uninfected HIV-infected p-Value
HBsAg positivea (%) 44/1546 (2.9) 53/1543 (3.4) 0.404
HBeAg positive, AntiHBe
negative (%)
7c/41b (15.9) 10/53 (18.9) 0.872
HBeAg negative, Anti-HBe
positive (%)
32c/41b (72.7) 43/53 (81.1) 0.912
HBV  DNA >10 IU/ml (%) 34/41 (77.2) 44/53 (83.0) 1.000
a Conﬁrmed by neutralisation.
b Three HBsAg-positive samples had insufﬁcient volumes left for further testing.
c One sample was negative for both HBeAg and anti-HBe and another one positive
or both HBeAg and anti-HBe. 31 (2013) 5579– 5584 5581
could be quantiﬁed was  similar in the HIV uninfected mothers
(27/32) and the co-infected mothers (34/43). Serum HBV DNA
loads was  of similar magnitude in the 27 HIV-uninfected women
(10–140,000 IU/ml, median 108 IU/ml) and the 34 HIV-infected
women (10–1,600,000 IU/ml, median 300 IU/ml) (Fig. 1 and
Table 2).
3.5. HBV genotyping, mutational analysis and phenotyping
HBV DNA sequence and genotype analysis was  successfully
undertaken on 25 and 43 samples from HIV-uninfected and HIV-
infected women, respectively. Phylogenetic analysis of HBsAg
indicated 63 persons to be infected with virus belonging to geno-
type A. The remaining ﬁve persons harboured genotype D viruses;
four were HIV-uninfected women and one HIV-infected. One HBV
sequence from an HIV-uninfected patient bore rtV173L alone, part
of the antiviral resistance proﬁle for lamivudine; none of the 42 HBV
sequences from the HIV-infected cohort carried detectable drug
resistance mutations.
Mapping of amino acid changes from the wild type consen-
sus sequence was  undertaken across the HBsAg region in order
to identify potential mutation ‘hot spots’ (Fig. 2). Two  samples
from HIV-uninfected and three from HIV-infected individuals car-
ried viruses with a number of coding changes between codons 120
and 150. One sample from an HIV-uninfected and two  from HIV-
infected mothers contained viruses carrying a premature stop at
codon 182. The signiﬁcance of changes outside codons 120–150 on
HBsAg antigenicity remain unknown.
Epitope mapping analysis was undertaken in 20 HIV-uninfected
and 33 HIV-infected mothers with HBV genotype A virus infec-
tion and HBsAg levels equal to or greater than 50 IU/ml. No antigen
exhibited major epitope ablation. However, the variations deﬁned
by SD exceedance were clearly more marked in the surface anti-
gen proﬁles in samples from HIV infected mothers (Fig. 3). Three
reactions falling outside 2 SD of the mean were seen in samples
from HIV-infected mothers. One virus carrying extensively mutated
HBsAg sequences (M1T, R79H, L98V, M133T, P135L, D144G, D194V)
and two  less scarred viruses (G44E, P203G/E and S204N) had reac-
tivities on one or more solid phases outside 2SD of the mean.
Mutations in the precore which impact on HBeAg expression
were found in 33% and 35% of samples from HIV-uninfected and
HIV-infected individuals respectively, with the loss of methionine
at codon 1 being the most commonly observed pathway for achiev-
ing e-null viruses constitutively unable to express HBeAg. The
A1762T/G1764A basal core promoter variant was observed at a
similar level (38%) in samples tested from both HIV-infected and
uninfected women. No signiﬁcant association between HBV DNA
level and the presence of these basal core promoter mutations or
pre-core mutations was noted in either patient group.
3.6. Antiretroviral drug residue testing
Antiretroviral drug residues were detected in three of 50 HIV-
HBV co-infected samples (1.5%). Lamivudine and nevirapine in two
and lamivudine and lopinavir in a third sample. Three samples were
of insufﬁcient volume for testing.
4. Discussion
Unlike data from well-resourced countries which show a sig-
niﬁcant difference in HBsAg prevalence in HIV-infected compared
to uninfected persons [16], this study conﬁrms previous antena-
tal data from Africa showing little difference in the prevalence of
HBsAg in HIV-infected compared with HIV-uninfected women, as
found elsewhere in South Africa, Côte D’Ivoire, Malawi and Tanza-
nia [17–20]. We have found however some evidence of loss of HBV
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Tig. 1. Median plasma HBV viral loads (expressed in IU/ml) according to HIV status i
s  box (interquartile range (IQR)) and whisker (range) plots.
mmune control in HIV co-infected women who demonstrated a
rend towards higher HBV viral loads.
In this antenatal population from the Western Cape, as many as
ne in six (18.1%) of HBV-infected mothers are HBeAg-seropositive
nd anti-HBe negative, irrespective of HIV status. This is a
igher proportion than expected and contrasts with Oshitani and
olleagues who found a difference in HBeAg prevalence in HIV-
nfected compared with HIV-uninfected women (25% vs. 12.3%)
21]. Our ﬁgure is lower than the high prevalence (5/12) of HBeAg
ositivity that we found previously in a cohort of HIV-HBV co-
nfected pregnant women with low CD4 counts attending a tertiary
eferral hospital [22]. This may  reﬂect differences in immune com-
etence between the two study cohorts. CD4 data was not available
or the current study to conﬁrm this suggestion.
ig. 2. ‘Hot spot’ analysis of amino acid changes across the HBsAg. Solid bars are sequence
he  circled area indicates amino acid changes in the major antigenic region between codg positive (left) and in HBeAg negative, anti-HBe positive (right) samples displayed
Although an association between high HBsAg prevalence and
low education was  found, the reasons for this are not clear. Low
educational attainment may  be a surrogate for rural childhood
where education is poorer than in urban areas, and HBsAg preva-
lence higher.
Our data also indicate that among HIV-uninfected women, those
whose serum contains HBeAg are signiﬁcantly younger than those
who are HBeAg seronegative. This raises the question of whether
HIV is having a population based effect on HBV epidemiology also
in the HIV-uninfected population.WHO  guidelines recommend HBV vaccine to be administered
within 24 h of delivery [23], however the ﬁrst HBV vaccine dose in
sub-Saharan Africa is given anytime between four and six weeks
postnatally, a time appropriate to prevent horizontal transmission,
s from 25 HIV-uninfected women and the hatched bars from HIV-infected women.
ons 120 and 150.
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Fig. 3. Epitope variance of plasma HBsAg expressed as box (middle quartiles) and
whiskers (range) in 20 HIV-uninfected and 33 HIV-infected women. Reactivity
against each monoclonal antibody solid phase is shown independently (MAb P2D3
is  against a linear epitope and MAbs HB07 and HB05 are against different conforma-
t
r
s
t
b
a
o
i
o
H
i
l
o
d
t
a
c
t
D
a
q
c
b
t
m
H
i
tional determinants in the second loop of HBsAg) and is expressed as the percentage
eactivity of each mAb  as part of the total reactivity for that sample.  denotes those
amples whose reactivity fell 2 standard deviations outside the expected range for
hat speciﬁc MAb.
ut probably too late to prevent reliably perinatal transmission
nd the evolution of persistent HBV infection. In light of this, our
bservations have important implications for current hepatitis B
mmunisation schedules in sub-Saharan Africa where the timing
f neonatal vaccine is predicated upon data generated before the
IV pandemic. This was at a time when HBeAg seropositive and, by
nference, high infectivity mothers were rarely encountered in the
abour wards [24]. Most mothers were therefore considered to be
f low infectivity. HBV transmission to infants was deemed to occur
uring early childhood [8] rather than through maternal–infant
ransmission in spite of one baseline HBV vaccine study reporting
 10.3% HBeAg prevalence in HBV-infected females [25]. Our data
learly indicate that contrary to previous beliefs, high HBV infec-
ivity mothers, whether deﬁned by HBeAg seropositivity or by HBV
NA, are not uncommon in the antenatal population in South Africa
nd indicate that current national vaccine schedules may  be inade-
uate to prevent mother-to-child transmission of HBV. Klingler and
olleagues have produced modelling data which suggest adding a
irth dose of HBV vaccine to the current regime may  be cost effec-
ive [26]. This may  not be as impractical as it ﬁrst seems given the
ajority of women in SSA give birth in health care facilities [27].
Although HBV DNA load is the most important predictor of
BV transmission from mother to child [7], HBeAg remains an
mportant marker for potential infectivity in pregnant women, par-
icularly in those situations where viral load estimates may  not be 31 (2013) 5579– 5584 5583
available. Not only is it associated with a high viral load, but it is
also thought to cross the placenta to tolerize the neonate leading
to an increased risk of chronic HBV infection [28]. HBeAg testing
is simple to implement, not expensive and may  still be useful in
resource poor settings to identify those women at increased risk of
transmitting HBV leading to viral persistence in their offspring.
Sequence analysis indicated the presence of codon changes
across the HBsAg, precore and basal core promoter regions. The
high prevalence of e-null viruses bearing pre-core/core and basal
core promoter mutations may indicate a propensity for early pro-
gression to serious liver disease in the future [29] and those making
health care predictions should bear this in mind. No HBV primary
resistance mutations were seen probably reﬂecting the fact that
very few women were on antiretroviral therapy, with antiviral drug
residues detected in only three out of 50 samples.
Variation in the HBsAg sequence in persistent HBV infections
was notable and seems phenotypically more common in the HIV co-
infected host. There was no instance of major epitope loss as can be
found in the classic vaccine escape G145R variant [14,30]. However,
the possible rescue by parturition of viruses bearing altered coding
and expression of HBsAg derived from HIV-infected mothers whose
viruses are beginning to escape host immune surveillance clearly
exists. Whether drug regimes where lamivudine is the sole HBV-
active agent which results in a signiﬁcant risk of developing HBV
resistance [31] could also potentiate the emergence of the vaccine
escape-like viruses [32,33] remains to be seen. In this study sur-
prisingly few women  were on antiretroviral therapy, in particular
few were on agents active against HBV, probably reﬂecting poor
roll-out of antiretroviral therapy at the time of the study. Never-
theless the possible infant rescue of viruses bearing altered HBsAg
lends urgency to the need to alter the timing of HBV immunisation
and the espousal of the more potent anti-HBV drugs like tenofovir
and entecavir for the treatment of those women  who are HBeAg
seropositive in the future.
There is one important limitation of this study which must
be considered when extrapolating from these data. The women
recruited to this study were only those who presented to antenatal
clinics for booking and a signiﬁcant part of the pregnant population
would have been excluded from this study through not attending
clinic. The reasons for poor access to health care are multiple and
range from ﬁnancial restraints, lack of understanding of the ben-
eﬁts of early booking to poor provision of health care services in
some areas. Those pregnant women who do not access antenatal
clinics are therefore more likely to have poorer access to health
care and potentially to have more advanced HIV disease. In these
women the loss of control of HBV is likely to be more profound and
they may  represent a reservoir of mutated HBV variants. However,
no immune status data in the HIV-infected women was collected
nor was  there any way to establish the timing of their HIV infection.
This study indicates that HIV-infected pregnant women, who
may  remain relatively well and immune-competent, nevertheless
have evidence of HBV escape when compared to HIV-uninfected
women. One in six HBV-infected pregnant women, irrespective of
HIV status, is HBeAg seropositive and likely to transmit HBV to their
offspring. These data support the call for a shift of HBV immunisa-
tion closer to the time of birth or, where this is deemed impractical
consideration should be given to the addition of a birth dose of
HBV vaccine to the current schedule. The data highlight the need
for further studies to determine the risk and virological outcome of
vertical transmission from mothers in this population.
AcknowledgementsWestern Cape Government and National Department of Health
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